

## PRESS RELEASE

November 21, 2016

For Press Enquiries: Michael R. Cohen, Chair, IMSN  
001-267-679-4767, [mcohen@ismp.org](mailto:mcohen@ismp.org)

### **IMSN Encourages Regulators and Companies to Improve Medication Safety at the Global Level**

**Toronto, Canada**—The **International Medication Safety Network (IMSN)** recognizes the unsafe naming, labeling and packaging of medicines as an ongoing, often unrecognized worldwide threat to patient safety that requires a collaborative approach. At a recent conference, IMSN called for greater action to standardize safe medication practices and improve medication safety internationally.

Medication errors affect millions of patients around the world, sometimes leading to death or serious harm. But in many instances, more attention needs to be paid to medication errors by regulatory authorities and industry, and the importance of human factors principles in the selection and design of medicine names, labels, and packaging is being overlooked. For example, not all regulators require companies to include bar codes on medication labels, which is essential for use of safety technologies at the bedside, in the operating room, or in the pharmacy. Too often, the issue of errors is being addressed in individual countries, but not on a global scale.

At the **IMSN Global Regulatory Meeting: Designing Medication Safety at the Global Level** held in Toronto, Canada on October 24, 2016, delegates from 17 member countries shared their views and concerns with invited regulators on factors that contribute to medication errors at a global level. The main regulators involved in this field, such as the US Food and Drug Administration (FDA), Health Canada, the European Medicine Agency (EMA), and the Medicines & Healthcare Products Regulatory Agency (MHRA), were joined by the World Health Organization (WHO) Patient Safety program. A separate session was held with major IV solution and technology companies on October 25, 2016, including Aguetant, Baxter Healthcare, B. Braun, BD/Carefusion, Hospira/Pfizer, Grifols, and Fresenius Kabi.

Participants agreed on the following actions to be addressed immediately to protect patients from medication errors at a global level:

-more-

- **Safer packaging** of medicines in ready-to-use forms, such as premixed intravenous infusions, prefilled syringes for high-alert injectable medications (including vaccines), and oral cytotoxics packaged in patient packs to support their specific posology;
- **Safer labeling** of medicines, including the presence of a bar code or other machine readable identification on each unit-of-use dosage form to facilitate use of available technologies now and in the future;
- **Safer medication labelling** with unequivocal expression of doses;
- **Metric graduations** on all dosing devices for oral liquids;
- **Safer nomenclature** by banishing dangerous abbreviations and umbrella brands;
- **Safer practices** in using medicines that easily expose patients to serious risks of error, such as opioids and acetaminophen/paracetamol;
- **Recognition of the expertise needed for analysis** (including an assessment for contributing factors in preventable adverse drug reactions) and prevention of medication errors, whether by promoting the role of medication safety officers or by encouraging premarket assessment of medicines and associated devices by manufacturers.

Participants agreed that effective bidirectional cooperation between safe practice centers, patient safety organizations and the pharmacovigilance community is needed.

In order to achieve a reduction of harm related to medication errors, harmonization at the global level also is necessary. The IMSN is committed to this harmonization of safe medication practices as they impact packaging and package labeling. Therefore, the IMSN is calling for a follow-up summit with regulatory authorities in order to establish minimum requirements and an action plan for medication safety worldwide.

Beyond product improvement, the IMSN supports the World Health Organization's Global Patient Safety Challenge on Medication Safety, through the participation of several IMSN members. IMSN members are contributing to the WHO initiative to tackle obstacles and propose solutions to improve the safety of medication practices.

**About IMSN:** The International Medication Safety Network (IMSN) is an international network of safe medication practice centers established with the aim of improving patient safety. This is achieved by operating medication error reporting programs and producing guidance to minimize preventable harm from medicine use in practice. IMSN promotes safer medication practices to improve patient safety internationally. For more information, visit: [www.intmedsafe.net/contents/AboutIMSN.aspx](http://www.intmedsafe.net/contents/AboutIMSN.aspx)

-end-